Triple-negative breast cancer
Triple-negative breast cancer (TNBC) is an aggressive molecular subtype of breast cancer defined by estrogen receptor and progesterone receptor negativity and by the absence of HER2 overexpression or amplification according to clinical thresholds.
Triple-negative breast cancer (TNBC) is an aggressive molecular subtype of breast cancer defined by estrogen receptor and progesterone receptor negativity and by the absence of HER2 overexpression or amplification according to clinical thresholds. Because it lacks these common therapeutic targets, TNBC is often managed with chemotherapy and, in selected settings, immunotherapy rather than endocrine or HER2-directed treatment. Biologically, TNBC is notable for high tumor cell proliferation, frequent invasiveness, and substantial heterogeneity across tumors and patients.
TNBC has been the focus of intensive research on the tumor microenvironment, immune suppression, metastasis, and mechanisms of treatment resistance. Recent studies have examined interactions with dendritic cell activity, CD274 molecule expression, transforming growth factor signaling, glutathione metabolism, reactive oxygen species handling, and processes such as apoptosis and ferroptosis. Experimental models often include MDA-MB-231 and MDA-MB-468 cells, as well as mouse models such as 4T1, to evaluate therapies combining chemotherapy, cisplatin, doxorubicin, taxane-based regimens, pembrolizumab, phototherapy, and nanoparticle platforms.
Where the papers sit
15 papers from the last 6 months study triple-negative breast cancer directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 2 observational · 6 human data · 6 preclinical · 1 unclassified
Themes 3 themes · 1 new direction
-
Tumor Microenvironment Immunotherapy
Tumor microenvironment remodeling is becoming a major route to improve immunotherapy in triple-negative breast cancer. ROS-generating nanomedicines, STING activation and phototherapy-induced senescence reprogramming seek to reverse immune suppression while enhancing chemotherapy. P188-mediated vascular stabilization offers another combination strategy, whereas Schwann cells, epithelial-mesenchymal transition and HER2-low status identify adverse immune contexts. Inferior immunotherapy response in HER2-low disease keeps patient selection and durable microenvironment control unresolved.
6 papers · 40%
-
Clinical Care and Outcomes
Neoadjuvant chemotherapy, mastectomy and postmastectomy radiation remain central to treatment, with pathologic complete response and recurrence shaping risk assessment. Real-world outcomes expose geographic and health-system barriers to timely care and clinical-trial participation. Microsimulation is extending this work toward individualized recurrence surveillance after standard treatment. Diagnostic separation of HER2-positive and triple-negative disease supports more precise treatment allocation, but outcome data remain heterogeneous.
5 papers · 33.3%
-
Cellular Stress and Differentiation
Cellular stress responses and differentiation states are emerging as guides to therapeutic sensitivity in triple-negative breast cancer. HSP90, the unfolded protein response, EIF2S1, heat-shock signaling and TFAP2B/FOXC1 define biologically distinct states. Androstene derivatives and bakuchiol are being explored as stress-targeting agents, including combinations with doxorubicin. Patient-derived organoids point toward biomarker-guided selection, but the most predictive markers remain unsettled.
4 papers · 26.7%
Tumor-associated Schwann cells establish a neural-stromal axis in triple-negative breast cancer
The study of Schwann-cell signatures in triple-negative breast cancer transcriptomic cohorts, validated by spatial transcriptomics and neoadjuvant-chemotherapy cohorts, treats tumor-associated nerves as a distinct biological component rather than framing TNBC only through tumor-cell, immune, or adipocyte features. It found that Schwann-cell signals localized to intratumoral nerve regions and were associated with epithelial–mesenchymal transition, an immunosuppressive microenvironment, and treatment-response patterns, making neural-associated stroma a new candidate axis for TNBC classification and therapeutic investigation 42573659Aug.
Papers
The 15 papers from the last 6 months that study triple-negative breast cancer directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Tumor Microenvironment Immunotherapy (6)
- Restoration of tumor vascular integrity by P188 improves chemotherapy and immunotherapy efficacy in triple negative breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 4 Sept 2026 PMID 42697039
- Association of tumor Schwann cells with epithelial-mesenchymal transition and immune-suppressive microenvironment in triple-negative breast cancer. Breast cancer research and treatment · 10 Aug 2026 PMID 42573659
- Self-exploding tumor microenvironment-responsive nanomedicine as "ROS Bomb" ignites STING pathway for triple-negative breast cancer immunotherapy. Journal of controlled release : official journal of the Controlled Release Society · 3 Aug 2026 PMID 42546818
- Distinct immune microenvironment in HER2-low triple-negative breast cancer underlies inferior response to immunotherapy. NPJ precision oncology · 17 Jun 2026 PMID 42310141
- Cytotoxic crosslinker-loaded indocyanine green nanoparticle for near-infrared fluorescence imaging-guided chemo-photothermal eradication of triple-negative breast cancer. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 13 Jun 2026 PMID 42288225
- NIR-II Imaging-Guided Phototherapy-Induced Senescence Reprograms Immunosuppressive Tumor Microenvironment for Potent Cancer Immunotherapy. ACS nano · 11 Jun 2026 PMID 42273756
Clinical Care and Outcomes (5)
- Geographic access to triple negative breast cancer clinical trials: are trials located near patients? Breast cancer research and treatment · 28 Sept 2026 PMID 42803985
- Recurrence detection in patients with triple-negative breast cancer following the current standard of care: a microsimulation model. BMJ open · 16 Sept 2026 PMID 42749377
- Prognostic factors and outcomes associated with postmastectomy radiation therapy following neoadjuvant chemotherapy and mastectomy for breast cancer: A retrospective cohort study. Medicine · 22 Aug 2026 PMID 42629708
- Neoadjuvant chemotherapy in women with triple-negative breast cancer: real world results from Western Kenya. The oncologist · 14 Aug 2026 PMID 42599194
- Breast Cancer Diagnosis and HER2+ Versus Triple Negative Discrimination by Infrared Spectral Histopathology. Analytical chemistry · 9 Jun 2026 PMID 42263021
Cellular Stress and Differentiation (4)
- Synthesis and biological evaluation of cyanoenone- and enone-fused 4-androstene-3,17-dione derivatives against triple-negative breast cancer. Bioorganic chemistry · 16 Sept 2026 PMID 42748754
- TFAP2B and FOXC1 are associated with biologically and clinically distinct differentiation states in triple-negative breast cancer. Scientific reports · 12 Sept 2026 PMID 42728354
- Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer. Cell reports. Medicine · 6 Aug 2026 PMID 42561946
- Exploring Bakuchiol as an HSP90-Targeting Lead Against Triple-Negative Breast Cancer: Evidence from In Silico, In Vitro, and Synergy Studies. Journal of computer-aided molecular design · 23 Jun 2026 PMID 42334659
By study type
Observational studies and case reports (2)
- Prognostic factors and outcomes associated with postmastectomy radiation therapy following neoadjuvant chemotherapy and mastectomy for breast cancer: A retrospective cohort study. Medicine · 22 Aug 2026 PMID 42629708
- Neoadjuvant chemotherapy in women with triple-negative breast cancer: real world results from Western Kenya. The oncologist · 14 Aug 2026 PMID 42599194
Human data, design not indexed (6)
- Geographic access to triple negative breast cancer clinical trials: are trials located near patients? Breast cancer research and treatment · 28 Sept 2026 PMID 42803985
- Recurrence detection in patients with triple-negative breast cancer following the current standard of care: a microsimulation model. BMJ open · 16 Sept 2026 PMID 42749377
- TFAP2B and FOXC1 are associated with biologically and clinically distinct differentiation states in triple-negative breast cancer. Scientific reports · 12 Sept 2026 PMID 42728354
- Association of tumor Schwann cells with epithelial-mesenchymal transition and immune-suppressive microenvironment in triple-negative breast cancer. Breast cancer research and treatment · 10 Aug 2026 PMID 42573659
- Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer. Cell reports. Medicine · 6 Aug 2026 PMID 42561946
- Breast Cancer Diagnosis and HER2+ Versus Triple Negative Discrimination by Infrared Spectral Histopathology. Analytical chemistry · 9 Jun 2026 PMID 42263021
Preclinical: animal, cell and lab studies (6)
- Synthesis and biological evaluation of cyanoenone- and enone-fused 4-androstene-3,17-dione derivatives against triple-negative breast cancer. Bioorganic chemistry · 16 Sept 2026 PMID 42748754
- Restoration of tumor vascular integrity by P188 improves chemotherapy and immunotherapy efficacy in triple negative breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 4 Sept 2026 PMID 42697039
- Self-exploding tumor microenvironment-responsive nanomedicine as "ROS Bomb" ignites STING pathway for triple-negative breast cancer immunotherapy. Journal of controlled release : official journal of the Controlled Release Society · 3 Aug 2026 PMID 42546818
- Exploring Bakuchiol as an HSP90-Targeting Lead Against Triple-Negative Breast Cancer: Evidence from In Silico, In Vitro, and Synergy Studies. Journal of computer-aided molecular design · 23 Jun 2026 PMID 42334659
- Cytotoxic crosslinker-loaded indocyanine green nanoparticle for near-infrared fluorescence imaging-guided chemo-photothermal eradication of triple-negative breast cancer. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 13 Jun 2026 PMID 42288225
- NIR-II Imaging-Guided Phototherapy-Induced Senescence Reprograms Immunosuppressive Tumor Microenvironment for Potent Cancer Immunotherapy. ACS nano · 11 Jun 2026 PMID 42273756
Unclassified: not yet indexed with MeSH (1)
- Distinct immune microenvironment in HER2-low triple-negative breast cancer underlies inferior response to immunotherapy. NPJ precision oncology · 17 Jun 2026 PMID 42310141
Written from 15 PubMed abstracts, each one listed by PMID above. Published: 2026-08-13. Last written: 2026-09-18 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.